Symptom dimensions and functional impairment in early psychosis: more to the story than just negative symptoms
- PMID: 23587696
- PMCID: PMC3663589
- DOI: 10.1016/j.schres.2013.03.024
Symptom dimensions and functional impairment in early psychosis: more to the story than just negative symptoms
Abstract
Functional impairment is a defining feature of psychotic disorders and usually appears well before their onset. Negative symptoms play a prominent role in the impaired functioning of individuals with schizophrenia and those at clinical-high-risk (CHR) for psychosis. Despite high rates of depression and anxiety in early psychosis, few studies have examined the contribution of these symptoms to functioning in the putative 'prodrome.' In the current study, we tested the hypotheses that 1) worse negative and disorganized, but not positive, symptoms would be significantly related to impaired social and role functioning in two cohorts of CHR individuals (combined N=98) and a separate sample of individuals with recent-onset (RO) psychotic disorders (N=88); and 2) worse anxiety and depression would be significantly related to impaired functioning in both samples, above and beyond the contributions of negative and disorganized symptoms. Findings largely supported our hypotheses that more severe negative and disorganized symptoms were related to poorer social and role functioning in both samples. Anxiety and depression severity were significantly related to poorer functioning in both samples. In addition, depression, but not anxiety, predicted poorer global and social functioning above and beyond that explained by negative symptoms in the CHR sample. These results suggest the need for phase-specific treatment in early psychosis, with a focus on symptom dimensions to improve functional outcomes for CHR individuals.
Copyright © 2013 Elsevier B.V. All rights reserved.
Conflict of interest statement
DM consults for Bristol Myers Squibb. CC has served as a one-time consultant for Pfizer, Merck, Lilly, Servier, and has received research funding from GlaxoSmithKline. SV is a paid consultant for Brain Plasticity Institute, Amgen, Hoffman La Roche, and Genentech. DF, TN, EF, BS, and RL declare no conflicts of interest.
References
-
- Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res. 1992;6(3):201–208. - PubMed
-
- Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res. 2011;125(1):54–61. - PubMed
-
- Amminger GP, Leicester S, Yung AR, Phillips LJ, Berger GE, Francey SM, McGorry PD. Early-onset of symptoms predicts conversion to non-affective psychosis in ultra-high risk individuals. Schizophr Res. 2006;84(1):67–76. - PubMed
-
- Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS) Iowa City, IA: University of Iowa; 1983.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
